Determine Immunoglobulin G4 (IgG4) Standards for Cow's Milk and Egg in Different Populations of Allergic and Non-allergic Children
NCT ID: NCT03776474
Last Updated: 2025-09-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
500 participants
OBSERVATIONAL
2020-11-18
2025-11-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Determine standards of plasma levels of casein-specific immunoglobulin G4 (IgG4) and egg-specific immunoglobulin G4 (IgG4) as a function of age, in non-allergic children, in allergic children, and in cured former allergic patients.
Analyze the plasma IgG4 / IgE ratio, according to the result of the oral provocation test (tolerance versus allergy) and, in the event of a reaction, according to the reactogenic dose (dose which caused the reaction).Determine whether analysis of the plasma metabolome can identify children with a cured allergy to cow's milk protein or to egg from those with a persistent allergy.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Immunoglobulin G4 and Immunoglobulin E Antibodies in a Population With Adverse Reactions to Foodstuffs-related Symptoms
NCT05681975
Food-specific IgG4-guided Elimination Diets Improve Allergy Symptoms in Children
NCT06063044
Non-Immunoglobulin E-mediated Food Allergies in Children
NCT04462978
An Observational Study of Childhood Food Allergy
NCT00356174
The Significance of a Timely Food Allergy Diagnosis and Optimal Surveillance of Nutritional Status in Children
NCT05287074
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
For instance, serum specific IgE positive values beyond which 95% of patients would have an allergic reaction have been proposed. These values are highly variable from one study to another because of methodological differences and heterogeneity of populations, and cannot be used in clinical practice.
The regular dosage of serum specific IgE and its evolution over time is used in clinical practice to predict a possible persistence of IgE mediated food allergy. Indeed, an initial high rate and/or elevation of specific IgE levels may be predictive of a persistent allergy, while initial low rates and a decrease in specific IgE may predict tolerance. When tolerance develops, there is a decrease in specific IgE levels, however, even if tolerance is obtained, they can remain positive at pathological levels.
During continuous exposure to an allergen, the specific immunoglobulin G4 (IgG4) response is physiological. Oral immunotherapy studies in food allergies showed an elevation of specific IgG4, associated with an elevation in the number of regulatory T lymphocytes (LTreg) and the production of interleukin (IL)-10. The development of spontaneous oral tolerance, without the intervention of immunotherapy, also seems to involve IgG4. In a prospective follow-up of a cohort of children with an IgE-mediated cow's milk allergy, the elevation of specific IgG4 was observed in those who cure of their allergy, with rates higher than those observed in children whose allergy persists. In children with cow's milk and/or egg allergies, a low concentration of specific (IgG4 of B-Lactoglobulin or ovalbumin is associated with the need for a more prolonged exclusion diet. The balance between specific IgE and IgG4 therefore appears to be important in the development of tolerance and may reflect the balance between effector T cells and LTreg. However, the normal serum levels of IgG4 to cow's milk and hen's egg are unknown.
A recently published study of Doctor Guillaume Lezmi and Professor Karine Adel-Patient shows that children with an IgE-mediated allergy to cow's milk protein and those who outgrew this allergy, have distinct plasma metabolomic signature. This suggests that plasma metabolomic analysis may be a useful too to differentiate children with a persistent cow's milk protein allergy from those who acquired tolerance to cow's milk. If confirmed, the metabolic signature may be useful to better identify children to whom an oral food challenge with cow's milk protein could be propose. These results need to be confirmed in a larger population and in other food allergies.
The study objectives are :
Determine standards of plasma levels of casein-specific immunoglobulin G4 (IgG4) and egg-specific immunoglobulin G4 (IgG4) as a function of age, in non-allergic children, in allergic children, and in cured former allergic patients.
Analyze the plasma IgG4 / IgE ratio, according to the result of the oral provocation test (tolerance versus allergy) and, in the event of a reaction, according to the reactogenic dose (dose which caused the reaction).
Determine whether analysis of the plasma metabolome can identify children with a cured allergy to cow's milk protein or to egg from those with a persistent allergy.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Allergic
Minors allergic to cow's milk and/or eggs
Blood collection
Patients less than 5 kg : 2 ml Patients over 5 kg : 3 ml Patients over 10 kg : 5 ml
Non-allergic
Minors without history of allergy to cow's milk and/or eggs
Blood collection
Patients less than 5 kg : 2 ml Patients over 5 kg : 3 ml Patients over 10 kg : 5 ml
Acquired tolerance
Minors formerly allergic to cow's milk and/or eggs
Blood collection
Patients less than 5 kg : 2 ml Patients over 5 kg : 3 ml Patients over 10 kg : 5 ml
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood collection
Patients less than 5 kg : 2 ml Patients over 5 kg : 3 ml Patients over 10 kg : 5 ml
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* In consultation or hospitalized for an oral food challenge for milk or eggs
* To undergo a blood test
Exclusion Criteria
1 Month
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
URC-CIC Paris Descartes Necker Cochin
OTHER
Assistance Publique - Hôpitaux de Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Guillaume Lezmi, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Assistance Publique - Hôpitaux de Paris
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hôpital Necker Enfants malades
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Adel-Patient K, Lezmi G, Castelli FA, Blanc S, Bernard H, Soulaines P, Dumond P, Ah-Leung S, Lageix F, de Boissieu D, Cortes-Perez N, Hazebrouck S, Fenaille F, Junot C, Dupont C. Deep analysis of immune response and metabolic signature in children with food protein induced enterocolitis to cow's milk. Clin Transl Allergy. 2018 Sep 28;8:38. doi: 10.1186/s13601-018-0224-9. eCollection 2018.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2018-A01972-53
Identifier Type: REGISTRY
Identifier Source: secondary_id
APHP180057
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.